TY - JOUR
T1 - Phospholipase A2 activity and calpactin I levels in rat lymphokine-activated killer cells
T2 - Correlation with the cytotoxic activity
AU - Cifone, M. Grazia
AU - Cironi, Luisa
AU - Roncaioli, Paola
AU - Martinotti, Stefano
AU - Toniato, Elena
AU - Cilenti, Lucia
AU - Botti, Dario
AU - Solito, Egle
AU - Parente, Luca
AU - Santoni, Angela
PY - 1996/6/15
Y1 - 1996/6/15
N2 - In the present paper we have shown evidence for a significant increase of type II sPLA2 activity in A-LAK cells. The A-LAX-mediated cytotoxicity against YAC-1 target cells was strongly inhibited by two inhibitors of sPLA2, p-BPB and mepacrine, suggesting the involvement of this enzyme in the lytic mechanism of A-LAK. On the other hand, stimuli such as A23187 ionophore and TPA, which were able to induce in control cells an increased AA release, failed to cause this effect in IL-2-treated cells, suggesting that PLA2 was not active in these cells. Thus, we analyzed the levels of calpactin I, which is considered to be involved in the down-regulation of PLA2 activity. HrIL-2 treatment led to an increased expression of calpactin I at both the RNA and the protein level. A substantial portion of calpactin I was associated with the external surface of A-LAK and was able to exert a strong inhibitory effect on a purified porcine pancreatic PLA2 activity in vitro. Our results suggest that the role of calpactin I could be relevant to regulate PLA2 activity, and to protect the effector cells against a possible toxic effect which this enzyme could exert if present at high levels.
AB - In the present paper we have shown evidence for a significant increase of type II sPLA2 activity in A-LAK cells. The A-LAX-mediated cytotoxicity against YAC-1 target cells was strongly inhibited by two inhibitors of sPLA2, p-BPB and mepacrine, suggesting the involvement of this enzyme in the lytic mechanism of A-LAK. On the other hand, stimuli such as A23187 ionophore and TPA, which were able to induce in control cells an increased AA release, failed to cause this effect in IL-2-treated cells, suggesting that PLA2 was not active in these cells. Thus, we analyzed the levels of calpactin I, which is considered to be involved in the down-regulation of PLA2 activity. HrIL-2 treatment led to an increased expression of calpactin I at both the RNA and the protein level. A substantial portion of calpactin I was associated with the external surface of A-LAK and was able to exert a strong inhibitory effect on a purified porcine pancreatic PLA2 activity in vitro. Our results suggest that the role of calpactin I could be relevant to regulate PLA2 activity, and to protect the effector cells against a possible toxic effect which this enzyme could exert if present at high levels.
UR - http://www.scopus.com/inward/record.url?scp=0030585387&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030585387&partnerID=8YFLogxK
U2 - 10.1006/cimm.1996.0161
DO - 10.1006/cimm.1996.0161
M3 - Article
C2 - 8660827
AN - SCOPUS:0030585387
VL - 170
SP - 274
EP - 282
JO - Cellular Immunology
JF - Cellular Immunology
SN - 0008-8749
IS - 2
ER -